Background Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. Currently, peripheral blood stem cells (PBSC) are infused after myeloablative therapy, but the eff ect of purging is unknown. We did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk neuroblastoma.
Introduction
High-risk neuroblastoma has a high rate of recurrence, most commonly in bone and bone marrow. 1 Results from the Children's Cancer Group (CCG)-3891 trial 2 showed that myeloablative chemotherapy with rescue with immunomagnetic bead purged autologous bone marrow improved outcome compared with conventional dose chemotherapy. Immunocytology can detect neuroblastoma tumour cells in the bone marrow. 3 Genetically labelled neuroblastoma cells infused from non-purged bone marrow can contribute to relapse after myeloablative therapy. 4 These data supported immunomagnetically purging bone marrow to remove tumour detectable by immunocytology, which has a sensitivity of one tumour cell in 10⁵ normal cells. 3 Currently, autologous peripheral blood stem cells (PBSC) are used to restore haemopoiesis after myeloablative therapy for high-risk neuroblastoma. Blood has no or fewer neuroblastoma cells detectable by immunocytology even when bone marrow is positive. 5 Quantitative real-time PCR (QrtPCR) can detect neuroblastoma mRNA in PBSC, [6] [7] [8] although the eff ect of infusing these PBSC has not been defi ned. We postulated that immunomagnetic bead purging would decrease tumour burden in PBSC and improve outcome. We report the results of the randomised Children's Oncology Group (COG) A3973 trial, which compared outcomes for high-risk neuroblastoma patients who received autologous purged versus non-purged PBSC after myeloablative chemotherapy. To our knowledge, this is the fi rst randomised study in any cancer to evaluate the eff ect of tumour-selective PBSC purging.
Methods

Study design and participants
This phase 3 trial was open from Feb 9, 2001 , to March 31, 2006, for children with high-risk neuroblastoma. Patients or parents or guardians provided written informed consent according to National Cancer Institute and local institutional review board guidelines.
Patients were enrolled from 95 COG member institutions in the USA (420) and Canada (66). Eligible patients had high-risk neuroblastoma according to the Children's Oncology Group (COG) criteria, including previously untreated neuroblastoma in patients younger than 1 year with International Neuroblastoma Staging System 9 (INSS) stage 3, 4, or 4S MYCN amplifi ed tumours and, in children aged 1 year or older, stage 4 tumours, stage 3 tumours with either unfavourable histology or MYCN amplifi cation, stage 2 tumours with unfavourable histology and MYCN amplifi cation, and initially low-risk patients treated with surgery only who later progressed with metastatic disease. 9 We excluded patients aged 12-18 months with stage 4 MYCN nonamplifi ed tumours and favourable histology, and hyperdiploid tumours after an amendment in May, 2004 . 10 Additional eligibility criteria included age up to 30 years, no previous history of chemotherapy, registration on companion biology study, ability to tolerate PBSC collection, and adequate cardiac, liver, and renal function.
Randomisation and masking
Patients were randomly assigned to treatment at study enrolment using the COG's online remote data entry system, which assigned treatment group in real-time based on the balance existing at that time, within blocks of size four. The method was random until such time as a random assignment exceeded the prespecifi ed margin of two within a block, and only then did the method become deterministic. Patients were randomly assigned (ratio 1:1) to receive either purged PBSC or non-purged PBSC at study entry; patients and treating physicians were not masked to this assignment. Randomisation was stratifi ed into blocks by International Neuroblastoma Staging System (INSS) stage, 9 age at diagnosis (<365 days or ≥365 days), MYCN gene status (amplifi ed or nonamplifi ed), and International Neuroblastoma Pathology Classifi cation (INPC; unfavourable or favourable).
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Procedures
All patients were prescribed identical chemotherapy, radiotherapy, and post-myeloablative isotretinoin (fi gure 1). Patients without progressive disease and adequate organ function received myeloablative carboplatin, etoposide, and melphalan, 12 with dose adjustment for glomerular fi ltration rate (GFR) lower than 100 mL/min per 1·73 m². 13 After local irradiation, patients could enrol in the COG ANBL0032 trial of isotretinoin plus chimeric anti-GD2 monoclonal antibody ch14.18, interleukin 2, and GM-CSF versus isotretinoin alone, 14 with randomisation stratifi ed by assigned arm of this study. We assessed response using the International Neuroblastoma Response Criteria. 9 We graded adverse events using the National Cancer Institute's Common Toxicity Criteria, version 2. 15 Reporting was required for all grade 3-5 toxic eff ects (non-targeted). To monitor safety during the study, the protocol required reporting of all grades of specifi c organ function and infectious toxic eff ects (targeted).
PBSC were collected after two induction cycles regardless of histological tumour content in the bone marrow. Requirements to proceed to consolidation were: immunocytology-negative PBSC with minimum of 1·5×10⁶ CD34 cells per kg for non-purged PBSC or minimum of 1×10⁶ viable CD34 cells per kg for purged PBSC. We determined viability on a thawed purged PBSC aliquot using trypan blue. 16 Patients with insuffi cient purged PBSC could receive non-purged PBSC (or purged bone marrow if non-purged PBSC also insuffi cient) meeting protocol criteria. Patients with immunocytology-positive non-purged PBSC could be recollected and purged. Purged PBSC were shipped frozen to the transplant institution and thawed immediately before reinfusion. We defi ned neutrophil engraftment as the fi rst of three consecutive absolute neutrophil counts of more than 500 cells per μL; and platelet engraftment as the fi rst of three consecutive platelet counts of more than 20 000 without transfusion.
Non-purged PBSC were cryopreserved at collecting sites. For purged PBSC, heparinised PBSC were transported overnight at ambient temperature to a centralised laboratory and purged the day after leukapheresis according to US Food and Drug Administration (FDA) IDE# BB-IDE 2259. PBSC were mixed with 200-300 mg of carbonyl iron per 10⁶ total cells to remove phagocytic cells and decrease the number of immunomagnetic beads required. Carbonyl iron and attached cells were removed using samarium cobalt magnets. Remaining cells were mixed with immunomagnetic beads using fi ve monoclonal antibodies targeting neuroblastoma cell surface antigens (459, HSAN 1·2, BA-1, HNK-1, and 126-4; appendix). Magnetic beads and attached cells were removed using samarium cobalt magnets. 16 Purged samples were suspended in L15 containing human serum albumin 10% volume/volume (Central Lab, Blood transfusion Service, Swiss Red Cross, Bern, Switzerland), hetastarch 1·5% weight/volume, and DMSO 10% volume/volume (Cryoserv, Ben Venue Laboratories Inc, Bedford, OH, USA) in Cryocyte Freezing bags (Baxter-Fenwal, Deerfi eld, NJ, USA). Stem-cell samples were also cryopreserved in 2 mL Cryovials (Baxter-Fenwal). All products were frozen with a rate-controlled programmed freezer (Cryomed) to -80°C and stored in liquid nitrogen vapour (150°C). Quality control of purged product required for release included immunocytology to detect neuroblastoma, CD34 viable content on post-purge test thaw sample, and endotoxin testing. Cryopreserved products were shipped to transplant centres in MVE LN2 dry shippers with constant temperature monitoring by overnight air delivery.
To detect neuroblastoma cells in PBSC, immuno cytology and TLDA assays were done on a PBSC aliquot from day 1 of leukapheresis on all patients before purging. Immunocytology after purging was done with mononuclear cells isolated by separation with FicollHypaque density media. Immunocytology used monoclonal antibodies against cell surface antigens (126-4, 390, 459, HSAN1·2, and BW575). 17, 18 The TLDA assay quantifi ed CHGA, DCX, DDC, PHOX2B, and TH mRNA expression. We deemed results to be detectable if one or more of the fi ve genes had a cycle threshold (C T ) value lower than 40 and to be undetectable if no signal was detected for any genes after 40 cycles (C T =40). We did a second analysis of the same data using only PHOX2B and TH mRNA expression to defi ne detectable samples (appendix).
Statistical analysis
Analyses were done by intention to treat. We targeted an enrolment of 486 patients, which would provide 80% power for a one-sided log-rank test of superiority of the purged group over the non-purged group at a level of 0·05, able to detect a 9% improvement in 2-year eventfree survival (38% vs 47%).
We did an intention-to-treat sequential monitoring of the trial, and considered early stopping if the groups proved 19 or would never prove 20 to be signifi cantly diff erent, or if the conditional power fell under 20%. We calculated the relative risk as the ratio of non-purged to purged using the planning variables for 2-year event-free survival, and under the alternative hypothesis, it would equal 1·33. The Fleming-Harrington-O'Brien 20 lower (futility) boundary was equivalent to repeated testing of the alternative hypothesis at p=0·005 for a cumulative α level of 0·05. The total expected information was 341 events. Only the COG data safety monitoring committee and study statistician were aware of interim effi cacy monitoring results. Trial effi cacy results remained masked until release by the data safety monitoring committee after all patients had completed protocol therapy. The primary endpoint was event-free survival, for which the time to event was calculated from study enrolment and randomisation until fi rst occurrence of relapse, progressive disease, secondary malignancy, death, or until last contact with the patient if no event occurred. For overall survival, the time to event was calculated from study enrolment until death, or until last contact with the patient. Post-hoc, we also calculated event-free survival and overall survival from the time of transplant. We generated Kaplan-Meier survival curves. 21 We report 5-year point estimates with 95% CI. 22 With the exception of the sequential monitoring, we deemed p values lower than 0·05 signifi cant. We did the statistical analyses using SAS version 9.2 and Stata version 12.1. This trial is registered with ClinicalTrials. gov, number NCT00004188. See Online for appendix
Role of the funding source
The NCI contributed to study design through scientifi c review. Alex's Lemonade Stand had no role in study design or reporting. Neither of these two funders had a role in data collection, data analysis, data interpretation, or writing of the report. All authors participated in writing the report and had full access to all the data in the study. The corresponding author had fi nal responsibility for the decision to submit for publication.
Results
The trial ended after 495 patients had been enrolled (patients were enrolled from March 16, 2001 , to Feb 24, 2006) . 486 patients were eligible for randomisation; 243 were randomly assigned to receive purged PBSC and 243 to receive non-purged PBSC (fi gure 2). Baseline characteristics were much the same in each group and seemed similar to the COG overall high risk cohort (table 1) . 2 Median age of the patients was 3·1 years (range 0·2-29·1 years). Of the 486 eligible for randomisation, 137 (28%) patients subsequently enrolled in the COG ANBL0032 trial after transplantation, and 78 (16%) were assigned to the ch14.18 antibody group (36 of 243 in the purged group and 42 of 243 in the non-purged group).
We obtained PBSC from 465 (96%) of 486 randomised patients: 229 in the purged group and 236 in the nonpurged group. Transplantation was completed in 372 patients (180 randomly assigned to purged and 192 to non-purged groups; fi gure 2). Reasons patients were not transplanted included progressive disease (28 from purged group and 25 from non-purged group) or death during induction (eight from purged group and seven from non-purged group), organ toxic eff ects (seven from purged group and fi ve from non-purged group), withdrawal from protocol (three from purged group), insuffi cient PBSC (fi ve from purged group and one from non-purged group), insuffi cient response (two from purged group and four from non-purged group), and other (ten from purged group and nine from non-purged group). 29 patients randomly assigned to purged PBSC could not comply because of insuffi cient PBSC yield for purging (12 patients) or after purging (eight patients), regulatory or technical issues (six patients), positive microbial culture of PBSC (one patient), and parental refusal (two patients). Five (1%) of 439 patients with immunocytology from day 1 of leukapheresis before purging had detectable tumour (table 1) . Four of these patients were randomly assigned to receive non-purged PBSC and underwent subsequent purged PBSC collection. The fi fth patient, also assigned to receive nonpurged PBSC, had a negative sample from day 1 immunocytology, but the pooled PBSC collection had positive immunocytology before purging. All fi ve patients had negative immunocytology after purging.
For the whole study population, 5-year event-free survival from enrolment was 38% (95% CI 34-42) and 5-year overall survival was 50% (95% CI 46-55), with median follow-up for patients without an event of 6·2 years (IQR 5·2-7·8). Neither event-free survival nor overall survival from enrolment diff ered between the purged and non-purged groups (fi gure 3A, B). We also noted no diff erence in event-free survival or overall survival from the time of transplantation between the purged and non-purged groups who completed transplantation (fi gure 3C, D). Post-hoc analysis by treatment actually received showed no diff erence in event-free survival (p=0·81) or overall survival (p=0·89) from study enrolment between groups; similar results were noted when event-free survival (p=0·15) and overall survival (p=0·23) were measured from time of transplantation (data not shown). In the 354 patients with stage 4 disease older than 18 months, event-free survival (p=0·32) or overall survival (p=0·77) from enrolment did not diff er between the purged and nonpurged groups. Outcome was similar for individuals with protocol-defi ned low compared with normal GFRs. Although potentially underpowered and done post-hoc, analyses suggested that 5-year event-free and overall survival for the 270 patients with stage 4 disease with invaded bone marrow at diagnosis did not signifi cantly diff er between groups (p=0·20 for event-free survival and p=0·50 for overall survival). Similarly, for the 120 patients who were stage 4 with invaded bone marrow after two cycles of chemotherapy (at the time of PBSC collection), there was no diff erence between groups in terms of 5-year event-free or overall survival (p=0·22 for event-free survival and p=0·52 for overall survival).
The 245 patients with TLDA results from day 1 of leukapheresis (before purging) were representative of all 486 patients in terms of clinical and prognostic characteristics (data not shown). Of these 245 patients, 122 (50%) had detectable tumour mRNA by the fi ve-gene TLDA: 68 (53%) of 129 patients in the purged group and 54 (47%) of 116 patients in the non-purged group (table 1) . Patients with detectable TLDA had lower event-free survival (at 5 years 29%, 95% CI 21-38) and overall survival (at 5 years 41%, 95% CI 32-50) than did patients with undetectable TLDA (5-year event-free survival 51%, 95% CI 42-60; p=0·0003; and 5-year overall survival 62%, 95% CI 53-70; p=0·0017; fi gure 4). When we analysed the same data using only expression of TH and PHOX2B, 62 (25%) patients had detectable TLDA (34 in the purged group and 28 in the non-purged group), with lower event-free survival (at 5 years 26%, 95% CI 16-37) and overall survival (at 5 years 35%, 95% CI 23-47) than those with undetectable TLDA (5-year event-free survival 45%, 95% CI 38-52; p=0·005; and 5-year overall survival 58%, 95% CI 50-65; p=0·01). 60 (33%) of 183 PBSC with undetectable two-gene TLDA (PHOX2B and TH; 34 in the purged group and 26 in the non-purged group) were detectable using fi ve genes.
Suffi cient numbers of CD34 cells per protocol criteria were obtained in 443 of 465 patients: 221 of 229 in the purged group and 222 of 236 in the non-purged group. GFR=glomerular fi ltration rate. *Stage 1 at diagnosis and progressed to stage 4 without interval chemotherapy. †All but two patients without day 1 immunocytological data had immunocytology testing on a separate stem-cell sample before stem cell-infusion for transplantation; treating physicians chose to infuse non-immunocytology tested products in those two patients. ‡Percentages calculated on the basis of the number of patients who were harvested and who had a specimen of suffi cient quality (129 purged, 116 non-purged, 245 overall). §One additional patient who received a transplant was retrospectively (post-transplant) determined by the treating institution to have had progressive disease at the end of induction. that occurred in 5% of patients or more. Ototoxic eff ects requiring amplifi cation (grade 3-4) occurred in 33 (7%) patients following induction (table 2) . Systemic fungal infection during induction occurred in 40 (8%) of 485 patients (18 in the purged group; 22 in the nonpurged group). There was no diff erence in consolidation toxic eff ects between the two randomised groups or the low versus normal GFR groups. 12 (7%) patients in the purged group and 17 (9%) of patients in the non-purged group had sinusoidal obstructive syndrome of grade 3 or higher. Sinusoidal obstructive syndrome was reported as severe in 15 (4%) patients (10 of 177 in the purged group, fi ve of 191 in the non-purged group), life-threatening in 13 (3%) patients (one of 177 in the purged group, 12 of 191 in the non-purged group), or fatal in one (<1%) patient in the purged group. The 15 (3%) deaths that occurred during induction were due to infection (four in the purged group and one in the non-purged group), tumour bleeding (three in the purged group and one in the non-purged group), tumour-related organ compromise (one in the purged group and two in the non-purged group), multi-organ failure (one death in non-purged group), unrelated event (one death in the non-purged group), and central venous line placement (one death in the purged group). Infectious deaths were from typhlitis (one death in the non-purged group), or fungal (two deaths in the purged group) and viral (two deaths in the purged group) causes. In the 12 (2%) deaths during consolidation (eight in the purged group and four in the non-purged group), causes included infection (three from adenovirus, one from cyto megalovirus, two from candida, one from aspergillus, and two bacterial infections), sinusoidal obstructive syndrome (one death), clinical sepsis with negative cultures (one death), and multi-organ failure (one death). In addition to the primary cause of death, fi ve patients also had sinusoidal obstructive syndrome as a contributing factor in their death.
Discussion
To our knowledge, this is the only randomised study of tumour-selective PBSC purging in any cancer (panel). Similar outcomes for the purged and non-purged groups establish that non-purged PBSC are acceptable for support of myeloablative therapy of high-risk neuroblastoma. Despite not requiring morphologically tumour-negative bone marrow before PBSC collection, only 1% of PBSC samples had tumour detectable by immunocytology; therefore, immunocytological testing of PBSC has been eliminated in COG studies.
The proportion of patients who achieved complete or very good partial response following induction chemotherapy in this trial was 51%, similar to other groups 24, 25 compared with 87·5% as originally reported (with small patient cohort at one institution). 26 Response and progressive disease rates were similar to the less intensive CCG 3891 induction, which had fewer induction deaths. 2 This trial escalated carboplatin, etoposide, and melphalan doses from the CCG 3891 regimen and omitted total body radiation (TBI), while maintaining a 5-year event-free survival similar to that reported in the myeloablative chemotherapy plus isotretinoin group from CCG 3891.
2 TBI was replaced with irradiation to the primary tumour site and post-induction MIBG avid metastatic sites. TBI is associated with short stature, cataracts, dental abnormalities, thyroid dysfunction, and radiation pneumonitis. 27 The toxic eff ects from the escalated chemotherapy regimen were tolerable, with sinusoidal obstructive syndrome of grade 3 or higher occurring in roughly the same proportion of patients as with the CCG 3891 CEM-TBI regimen, 2 where it led to death in 3% of patients. Similar results were obtained in a pilot study of tandem high dose chemotherapy using cyclophosphamide and thiotepa followed by CEM with PBSC rescue. 12 Immunomagnetic purging of PBSC did not improve outcome, possibly because of incomplete purging or due to residual tumour in patients. In preclinical modelling, immunomagnetic purging removed 3-4 logs of tumour cells from bone marrow when starting with 10-20% tumour cells. 16 All fi ve PBSC products with tumour detected by immunocytology from the sample of day 1 became undetectable after purging, which supports a purging eff ect. The number of randomised patients achieving complete response were insuffi cient to resolve the issue of whether residual tumour in patients was a possible cause for the failure of purging to improve outcome. All patients received isotretinoin and similar numbers of patients from both groups received postconsolidation ch14.18 antibody plus cytokines. This postconsolidation therapy might have eliminated tumour cells infused in the stem-cell product, which could obscure an eff ect of purging.
Apheresis was planned after cycle two of induction to obtain adequate CD34 cell per kg yield and avoid stemcell exposure to topoisomerases to decrease secondary leukaemia risk. 26 Results from a previous study 5 showed a very low incidence of immunocytology-detectable tumour in PBSC even when bone marrow contained residual neuroblastoma at the time of pheresis. 5 This result was confi rmed in our current study, with only 1·2% of PBSC products having immunocytologydetectable tumour.
We assessed TLDA on an aliquot of PBSC from day 1 of leukapheresis to assess the prognostic signifi cance of TLDA before any manipulation of PBSC for all patients. *A given patient is counted once for a given toxicity at the highest grade within a treatment period. †One patient in the purged transplantation group died on day of enrolment, never received any treatment, and was therefore excluded from toxicity analysis. ‡Targeted toxic eff ects: selected organ or infectious toxic eff ects with mandatory reporting of all grades. §Non-targeted toxic eff ects: required reporting of all grade 3-5 toxic eff ects. ¶Data were not reported regarding toxicity for three patients in the purged transplantation group and one patient in the non-purged transplantation group. ||There were no non-targeted toxic effects of grades 3-5 that were noted in more than 5% of patients. Our analysis showed a detectable signal by fi ve-gene TLDA was associated with a worse outcome. We did an additional analysis of our TLDA data using only TH and PHOX2B expression to compare with other studies. [6] [7] [8] Our patients with a detectable signal with either TH or PHOX2B also had signifi cantly worse outcome compared with those patients with an undetectable signal. A higher number of patients had a detectable signal with the fi vegene than with the two-gene analysis, providing more sensitive or less specifi c, or both, tumour mRNA detection. Thus, TLDA analysis of PBSC provides novel prognostic information that might provide early identifi cation of patients requiring alternative therapy. Smaller series have shown confl icting results regarding the prognostic value of minimum tumour detection in PBSC. [6] [7] [8] Data from other groups support the prognostic signifi cance of QrtPCR detection of neuroblastoma mRNA in bone marrow. 28, 29 An international task force is currently assessing QrtPCR methodologies to reach a consensus for implementing this technology. 30 Multivariable analysis of signifi cance of TLDA compared with other prognostic factors is ongoing. Further analyses that are still in progress include the detection of tumour mRNA by fi ve-gene TLDA in bone marrow and peripheral blood and multivariate analysis of TLDA, MIBG score, bone marrow morphology, and overall clinical response.
The study was designed to assess the eff ect of purging in patients with high-risk neuroblastoma as defi ned by the COG. It was not powered to assess outcome in the subset of patients with stage 4 disease aged 18 months or older. However, because of the insuffi cient evidence for an outcome diff erence in the treatment groups, this limitation became a non-issue. Another potential limitation is the lack of data from TLDA analyses before and after purging. Although we measured this in a subset of patients, the purging methodology might have caused technical interference with interpretation of the TLDA assay, which would prevent accurate quantifi cation of the tumour mRNA reduction after purging. As such, we have not presented these data.
In conclusion, our results support the use of nonpurged PBSC products following myeloablative therapy of high-risk neuroblastoma.
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